Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 2
---
,442 Shares of Common Stock Underlying the Pre-Funded Warrants and Up to 297,397.768 Shares of Series B Preferred Stock Underlying Series A Warrants and Series B WarrantsWe are offering units (the “Units”), each Unit consisting of one share of our common stock, $0.0001 par value per share (“common stock”), and an accompanying Series A warrant (the “Series A Warrants”) to purchase 0.001 share of Series B Convertible Preferred Stock and an accompanying Series B warrant (the “Series B Warrants”, and, with the Series A Warrants, the “Series Warrants”) to purchase 0.001 share of Series B Convertible Preferred Stock (“Series B Preferred Stock”), at the assumed public offering price of $0.269 per Unit, which was the last reported sales price of our common stock on The Nasdaq Capital Market on February 6, 2025.We are also offering the shares of Series B Preferred Stock that are issuable from time to time upon exercise of the Series Warrants contained in the Units. We do not currently have a sufficient number of authorized shares of common stock to cover the shares issuable upon the conversion of Series B Preferred Stock. As a result, before any shares of Series B Preferred Stock can become convertible, we are required to receive stockholder approval of an amendment (the “Charter Amendment”) to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to sufficiently increase our authorized shares of common stock to cover the conversion of all outstanding shares of Series B Preferred Stock into common stock. In addition to the Charter Amendment, the Company is required to obtain stockholder approval as may be required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any successor entity), but not limited to, with respect to (i) the issuance of all of the shares of common stock issuable upon conversion of the Series Warrant Shares upon the exercise the Series Warrants in accordance with their terms (including adjustment provisions set forth therein), and (ii) to consent to any adjustment to the exercise price or number of shares of Series B Preferred Stock underlying the Series Warrants in the event of a Share Combination Event, Dilutive Issuance and Reset Date (as defined in the Series B Warrants) (collectively, the “Stockholder Approval”). We have agreed to use our reasonable best efforts to obtain such approval within 60 days from the closing of this offering, and agreed to cause an